ClinicalTrials.gg
RecruitingNCT07302347Updated Jul 13, 2026

A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)

A Phase 1/2 interventional study of Pembrolizumab in Malignant Neoplasm, Carcinoma, Merkel Cell and Lymphoma, sponsored by Merck Sharp & Dohme LLC. Recruiting at 7 sites in Japan. Open to participants aged 6 Months and older. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
6 Months and older
Sex
All
01

Study summary

Researchers are looking for new ways to treat people with solid tumors, lymphomas (blood cancers), and a certain type of skin cancer. The goals of this study are to learn:

  • About the safety of pembrolizumab (the study medicine) and if people tolerate it
  • What happens to different doses of pembrolizumab in a person's body over time
  • How the cancer responds (gets smaller or goes away) to treatment
02

Conditions studied

  • Malignant Neoplasm
  • Carcinoma, Merkel Cell
  • Lymphoma
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 20 is below the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

Arm 1:

  • For participants with classical Hodgkin lymphoma (cHL) or primary mediastinal large B-cell lymphoma (PMBCL)

    • Has a confirmed diagnosis of relapsed or refractory cHL or PMBCL after the most recent therapy
    • Has radiographically per Lugano classification
  • For participants with completely resected melanoma:

    • Has surgically completely resected and histologically/ confirmed diagnosis of Stage IIB, IIC, III or IV cutaneous melanoma
    • Has not received any prior systemic therapy for their melanoma beyond surgical resection
    • All suspicious lesions amenable to are confirmed negative for
  • For participants with locally advanced or melanoma:

    • Has histologically confirmed diagnosis of locally advanced (unresectable Stage III) or metastatic (Stage IV) melanoma (including acral) not amenable to local therapy
    • Has radiographically measurable lesion(s) as defined by 1.1
  • For participants with microsatellite instability-high (MSI-H)/mismatch repair deficiency (dMMR) solid tumors:

    • Has histologically/cytologically documented, locally-advanced, or metastatic solid malignancy that is incurable and has either (a) failed prior standard therapy, (b) for which no standard therapy exists, or (c) standard therapy is not considered appropriate by the participant and treating physician
    • Has a documented positive local MSI-H or dMMR test result
    • Has radiographically measurable disease based on RECIST 1.1
  • For participants with tumor mutational burden-high (TMB-H) solid tumors:

    • Has histologically/cytologically documented, locally-advanced, or metastatic solid malignancy that is incurable and has either (a) failed prior standard therapy, (b) for which no standard therapy exists, or (c) standard therapy is not considered appropriate by the participant and treating physician
    • Has radiographically measurable disease based on RECIST 1.1
  • For participants with MCC:

    • Has histologically confirmed diagnosis of locoregional MCC that has recurred following standard locoregional therapy with surgery and/or radiation therapy and is not amenable to local therapy or metastatic MCC (Stage IV)
    • Has radiographically measurable disease based on RECIST 1.1

Arm 2:

  • For participants with MCC:

    • Has been untreated for advanced or metastatic disease

Arm 1 \& Arm 2:

  • of >3 months (Arm 1) or >6 months (Arm 2)

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has known additional that is progressing or has required active treatment
  • Has known active (central nervous system) and/or carcinomatous meningitis
  • Has active disease that has required systemic treatment in past 2 years
  • Has history of (noninfectious) pneumonitis/interstitial lung disease that required or has current pneumonitis/interstitial lung disease
  • Has active infection requiring systemic therapy
  • Has known history of (HIV) infection
  • Has known history of infection or known active virus
  • Has undergone solid organ transplant at any time, or prior hematopoietic stem cell transplantation within the last 5 years
  • Has not adequately recovered from major surgery or has ongoing surgical complications
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Arm 1: Pembrolizumab in Pediatric Participants with Solid Tumors or Lymphomas

    Pediatric participants with solid tumors or lymphomas receive 2 mg/kg pembrolizumab via intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21 day cycle for up to 17 or 35 cycles.

    Biological: Pembrolizumab

  • Experimental
    Arm 2: Pembrolizumab in Adult Participants with Merkel Cell Carcinoma (MCC)

    Adult participants with MCC receive 400 mg pembrolizumab via IV infusion on Day 1 of each 42 day (6 week) cycle, for up to 18 cycles.

    Biological: Pembrolizumab

Interventions

  • BiologicalPembrolizumab

    25 mg/mL solution for intravenous infusion.

    Also known as: MK-3475

06

What researchers measure

Primary outcomes

  1. Arm 1: Number of Participants Who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a study intervention. The number of participants with solid tumors or lymphomas who experience an AE will be reported.

    Time frame: Up to approximately 28 months

  2. Arm 1: Number of Participants Who Discontinue Study Treatment Due To an AE

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a study intervention. The number of participants with solid tumors or lymphomas who discontinue study treatment due to an AE will be reported.

    Time frame: Up to approximately 25 months

  3. Arm 1: Area Under the Concentration-Time Curve (AUC) of Pembrolizumab

    AUC is defined as the area under the concentration-time curve of pembrolizumab. Blood samples will be collected at specified intervals for the determination of AUC. AUC in participants with solid tumors or lymphomas will be reported.

    Time frame: Predose at Cycle 1, 2, 4, 8 and every 4 cycles thereafter up to 35 cycles; postdose at Cycle 1 and Cycle 8 (a cycle is 21 days)

  4. Arm 1: Maximum Concentration (Cmax) of Pembrolizumab

    Cmax is defined as the maximum concentration of pembrolizumab reached. Blood samples will be collected at pre-specified intervals for the determination of Cmax. Cmax in participants with solid tumors or lymphomas will be reported.

    Time frame: Predose at Cycle 1, 2, 4, 8 and every 4 cycles thereafter up to 35 cycles; postdose at Cycle 1 and Cycle 8 (a cycle is 21 days)

  5. Arm 1: Minimum Plasma Concentration (Cmin) of Pembrolizumab

    Cmin is defined as the minimum concentration of pembrolizumab observed in plasma after its administration and just prior to administration of a subsequent dose. Blood samples will be collected at pre-specified timepoints to determine Cmin. Cmin in participants with solid tumors or lymphomas will be reported.

    Time frame: Predose at Cycle 1, 2, 4, 8 and every 4 cycles thereafter up to 35 cycles; postdose at Cycle 1 and Cycle 8 (a cycle is 21 days)

  6. Arm 2: Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR)

    ORR is defined as complete response (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by blinded independent central review (BICR). ORR in participants with Merkel cell carcinoma will be reported.

    Time frame: Up to approximately 37 months

Secondary outcomes

  1. Arm 1: ORR per RECIST 1.1 by Investigator Assessment

    ORR is defined as complete response (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 by investigator assessment. ORR in participants with solid tumors will be reported.

    Time frame: Up to approximately 46 months

  2. Arm 1: ORR per Lugano Classification by Investigator Assessment

    ORR is defined as complete response (CR: all target lymph nodes must have regressed to normal size defined as ≤1.5 cm in longest diameter) or partial response (PR: ≥50% decrease in sum of products of diameters of target lesions from baseline, and no individual lesion meets the criteria for progression), per Lugano classification (Cheson et al, Journal of Clinical Oncology, 2014). ORR in participants with lymphomas as assessed by investigator will be reported.

    Time frame: Up to approximately 46 months

  3. Arm 1: Duration of Response (DOR) per RECIST 1.1 by Investigator Assessment

    For participants who demonstrate a complete response (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR per RECIST 1.1 by investigator assessment in participants with solid tumors will be reported.

    Time frame: Up to approximately 46 months

  4. Arm 1: DOR per Lugano Classification by Investigator Assessment

    For participants who demonstrate confirmed CR or PR, DOR is defined as the time from the first documented evidence of CR (all target lymph nodes must have regressed to normal size defined as ≤1.5 cm in longest diameter) or PR (≥50% decrease in sum of products of diameters of target lesions from baseline, and no individual lesion meets the criteria for progression) per Lugano classification (Cheson et al, Journal of Clinical Oncology, 2014) until progressive disease (PD: based on the progression of any single lesion and other certain requirements) or death due to any cause, whichever occurs first. DOR in participants with lymphomas as assessed by investigator will be reported.

    Time frame: Up to approximately 46 months

  5. Arm 1: Disease Control (DCR) per RECIST 1.1 by Investigator Assessment

    DCR is defined, per RECIST 1.1, as the percentage of participants who have a CR or PR or stable disease (SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease \[PD: At least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD\]). DCR per RECIST 1.1 by investigator assessment in participants with solid tumors will be reported.

    Time frame: Up to approximately 46 months

  6. Arm 1: DCR per Lugano Classification by Investigator Assessment

    DCR is defined as confirmed CR (all target lymph nodes must have regressed to normal size defined as ≤1.5 cm in longest diameter), PR (≥50% decrease in sum of products of diameters of target lesions from baseline, and no individual lesion meets the criteria for progression), or stable disease (SD: Target lesions do not meet the criteria for CR or PR and no individual lesion meets the criteria for progression) per Lugano classification (Cheson et al, Journal of Clinical Oncology, 2014). DCR in participants with lymphomas as assessed by investigator will be reported.

    Time frame: Up to approximately 46 months

  7. Arm 1: Progression-free Survival (PFS) per RECIST 1.1 by Investigator Assessment

    PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by RECIST 1.1. PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS per RECIST 1.1 by investigator assessment in participants with solid tumors will be reported.

    Time frame: Up to approximately 46 months

  8. Arm 1: PFS per Lugano Classification by Investigator Assesment

    PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by Lugano classification (Cheson et al, Journal of Clinical Oncology, 2014) by investigator. PD per Lugano classification is defined as based on the progression of any single lesion and other certain requirements. PFS in participants with solid tumors will be reported.

    Time frame: Up to approximately 46 months

  9. Arm 1: Relapse-free Survival (RFS) per RECIST 1.1 by Investigator Assessment

    RFS is defined only for adjuvant melanoma participants as the time from first dose to recurrence of melanoma at any site (local, in-transit or regional lymph nodes or distant recurrence) per RECIST 1.1 by investigator assessment or death due to any cause, whichever occurs first. New incident cases of melanoma and second cancer diagnoses are not counted as events for recurrence-free survival. RFS in participants with solid tumors or lymphomas will be reported.

    Time frame: Up to approximately 46 months

  10. Arm 1: Distant Metastasis-free Survival (DMFS) per RECIST 1.1 by Investigator Assessment

    DMFS is defined only for adjuvant melanoma participants as the time from first dosing to the first diagnosis of a distant metastasis per RECIST 1.1 by investigator assessment or death (due to any cause), whichever occurs first. Distant metastasis refers to cancer that has spread from the original (primary) tumor and beyond local tissues and lymph nodes to distant organs or distant lymph nodes. DMFS in participants with solid tumors or lymphomas will be reported.

    Time frame: Up to approximately 46 months

  11. Arm 1: Overall Survival (OS)

    OS is defined as the time from the first dose of study intervention to death due to any cause. OS in participants with solid tumors or lymphomas will be reported.

    Time frame: Up to approximately 46 months

  12. Arm 1: Number of Participants with Anti-Drug Antibodies (ADAs) Against Pembrolizumab

    Blood samples will be collected at multiple time points to determine the ADA response to pembrolizumab. The number of participants with ADA for pembrolizumab in participants with solid tumors or lymphomas will be reported.

    Time frame: Predose at Cycle 1, 2, 4, 8 and every 4 cycles thereafter up to 35 cycles (a cycle is 21 days)

  13. Arm 2: ORR per RECIST 1.1 by Investigator Assessment

    ORR is defined as complete response (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 by investigator assessment. ORR in participants with Merkel cell carcinoma will be reported.

    Time frame: Up to approximately 46 months

  14. Arm 2: DOR per RECIST 1.1 by BICR

    For participants who demonstrate a complete response (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR per RECIST 1.1 by BICR in participants with Merkel cell carcinoma will be reported.

    Time frame: Up to approximately 46 months

  15. Arm 2: DOR per RECIST 1.1 by Investigator Assessment

    For participants who demonstrate a confirmed CR: disappearance of all target lesions or PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR by investigator assessment in participants with Merkel cell carcinoma will be reported.

    Time frame: Up to approximately 46 months

  16. Arm 2: DCR per RECIST 1.1 by BICR

    DCR is defined, per RECIST 1.1, as the percentage of participants who have a CR or PR or stable disease (SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease \[PD: At least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD\]). DCR per RECIST 1.1 by BICR in participants with Merkel cell carcinoma will be reported.

    Time frame: Up to approximate ly 46 months

  17. Arm 2: DCR per RECIST 1.1 by Investigator Assessment

    DCR is defined, per RECIST 1.1, as the percentage of participants who have a CR or PR or stable disease (SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD: At least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD). DCR per RECIST 1.1 by investigator assessment in participants with Merkel cell carcinoma will be reported.

    Time frame: Up to approximately 46 months

  18. Arm 2: PFS per RECIST 1.1 by BICR

    PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by RECIST 1.1. PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS per RECIST 1.1 by BICR in participants with Merkel cell carcinoma will be reported.

    Time frame: Up to approximately 46 months

  19. Arm 2: PFS per RECIST 1.1 by Investigator Assesment

    PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by RECIST 1.1. PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS per RECIST 1.1 by investigator assessment in participants with Merkel cell carcinoma will be reported.

    Time frame: Up to approximately 46 months

  20. Arm 2: OS

    OS is defined as the time from the first dose of study intervention to death due to any cause. OS in participants with Merkel cell carcinoma will be reported.

    Time frame: Up to approximately 46 months

  21. Arm 2: Cmax of Pembrolizumab

    Cmax is defined as the maximum concentration of pembrolizumab reached. Blood samples will be collected at pre-specified intervals for the determination of Cmax. Cmax in participants with Merkel cell carcinoma will be reported.

    Time frame: Predose at Cycles 1-4, and every 2 cycles thereafter up to 18 cycles; postdose at Cycle 1 and Cycle 3 (a cycle is 42 days)

  22. Arm 2: Cmin of Pembrolizumab

    Cmin is defined as the minimum concentration of pembrolizumab observed in plasma after its administration and just prior to administration of a subsequent dose. Blood samples will be collected at pre-specified timepoints to determine Cmin. Cmin in participants with Merkel cell carcinoma will be reported.

    Time frame: Predose at Cycles 1-4, and every 2 cycles thereafter up to 18 cycles; postdose at Cycle 1 and Cycle 3 (a cycle is 42 days)

  23. Arm 2: Number of Participants Who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a study intervention. The number of participants with Merkel cell carcinoma who experience an AE will be reported.

    Time frame: Up to approximately 28 months

  24. Arm 2: Number of Participants Who Discontinue Study Treatment Due To an AE

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a study intervention. The number of participants with Merkel cell carcinoma who discontinue study treatment due to an AE will be reported.

    Time frame: Up to approximately 25 months

07

Study locations

7 of 7 sites recruiting
  • Nagoya City University Hospital ( Site 0003)
    Nagoya, Aichi-ken 467-8602, Japan
    Recruiting
    • Study Coordinator · Contact+81-52-851-5511
  • Nagoya City University Hospital ( Site 0007)
    Nagoya, Aichi-ken 467-8602, Japan
    Recruiting
    • Study Coordinator · Contact+81-52-851-5511
  • Sapporo Hokuyu Hospital ( Site 0005)
    Sapporo, Hokkaido 003-0006, Japan
    Recruiting
    • Study Coordinator · Contact+81-11-865-0111
  • Hyogo Prefectural Kobe Children's Hospital ( Site 0006)
    Kobe, Hyōgo 650-0047, Japan
    Recruiting
    • Study Coordinator · Contact+81-78-945-7300
  • National Cancer Center Hospital ( Site 0002)
    Chūō, Tokyo 104-0045, Japan
    Recruiting
    • Study Coordinator · Contact+81-3-3542-2511
  • National Hospital Organization Kyushu Cancer Center ( Site 0001)
    Fukuoka, 811-1395, Japan
    Recruiting
    • Study Coordinator · Contact+81-92-541-3231
  • University Hospital,Kyoto Prefectural University of Medicine ( Site 0004)
    Kyoto, 602-8566, Japan
    Recruiting
    • Study Coordinator · Contact+81-75-251-5111
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Mar 2029, 33 months after the start.

Of 195 industry-sponsored phase 1/2 interventional studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 88. This study's planned 33 months is below that.

Counting every sponsor, half of 297 studies reached it within 60 months; a quarter within 39 and three quarters within 89.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2025
First posted
Dec 24, 2025
StartActual
Jun 23, 2026
Primary completionEst.
Mar 30, 2029
CompletionEst.
Dec 31, 2029
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07302347
Responsible party
Sponsor
First posted
Dec 24, 2025
Start date
Jun 23, 2026
Primary completion
Mar 30, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Jul 13, 2026

Study contacts

Toll Free Number
Contact
Trialsites@msd.com
1-888-577-8839
Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pembrolizumab

Start the discussion